Crossmark

Acute COVID-19 severity markers predict post-COVID new-onset psychiatric disorders: A 2-year cohort study of 34,489 patients

Crossref DOI link: https://doi.org/10.1038/s41380-024-02739-7

Published Online: 2024-09-16

Published Print: 2025-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gasnier, Matthieu https://orcid.org/0000-0003-4887-4025
Pinson, Pierre

Beeker, Nathanael

Truong-Allié, Camille

Becquemont, Laurent https://orcid.org/0000-0003-3477-8956
Falissard, Bruno

Corruble, Emmanuelle

Colle, Romain
License Information

Text and Data Mining valid from 2024-09-16

Version of Record valid from 2024-09-16
More Information

Article History

Received: 28 December 2023

Revised: 26 August 2024

Accepted: 29 August 2024

First Online: 16 September 2024

Competing interests

: Bruno Falissard has been a consultant or speaker for Abbvie, Actelion, Allergan, Almirall, Alnylam, Amgen, Astellas, Astrazeneca, Bayer, Biogen, Biopecs, Bioproject, Biotronik, BMS, Boehringer, Celgène, Daiichi-Sankyio, Ethypharm, Forestlab, Genevrier, Genzyme, Gilead, Grünenthal, GSK, Idorsia, IMS, Indivior, IQVIA, JNJ, Léo, Lilly, Lundbeck, Menarini, MSD, Novartis, Novonordisk, Otsuka, Pfizer, Pierre-Frabre, Recordati, Roche, SANOFI, Servier, Takeda, UCB, ViiV, and Wellmera outside the submitted work. Laurent Becquemont has been a speaker Sanofi Genzyme out of the submitted work. Matthieu Gasnier, Pierre Pinson, Emmanuelle Corruble, Nathanaël Beeker, Camille Truong-Allie and Romain Colle have no conflict of interest.

: All methods were performed in accordance with the relevant guidelines and regulations. This study was approved by the Institutional Review Board of the AP-HP clinical data warehouse (“Entrepôt de Données de Santé (EDS)”, IRB number: IRB00011591). Informed consent was obtained from all participants

Document is current

Any future updates will be listed below